Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3492737 | 0.89 | KMT2A (0.67) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL3496064 | 0.85 | KMT2A (0.62) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL3494528 | 0.83 | KMT2A (0.68) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL3494402 | 0.83 | KMT2A (0.49) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL13348084 | 0.82 | KMT2A (0.50) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL3494473 | 0.82 | KMT2A (0.62) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL13348144 | 0.81 | KMT2A (0.63) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL14222291 | 0.78 | KDM4E (0.50) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL24183527 | 0.78 | SMN1; SMN2 (0.57) | KMT2AMEN1KDM4EPOLBNPC1 | |
| SCHEMBL24183637 | 0.77 | SMN1; SMN2 (0.58) | KMT2AMEN1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | KMT2A 2374/4885MEN1 2745/4885KDM4E 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.